T cell immunophenotypes and IgE responses in patients with moderate‐to‐severe atopic dermatitis receiving dupilumab
Abstract Background Targeting the interleukin‐4 receptor alpha (IL‐4Rα) subunit has proven clinical efficacy in atopic dermatitis (AD). Objective This study assessed the peripheral phenotype and function of T‐cells, but also levels of total and sIgE and its receptors in AD patients receiving dupilum...
Saved in:
| Main Authors: | Davender Redhu, Wojciech Francuzik, Philipp Globig, Margitta Worm |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Clinical and Translational Allergy |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/clt2.70062 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
[Artículo traducido] Alteraciones analíticas durante el tratamiento con dupilumab para la dermatitis atópica
by: D. Flor, et al.
Published: (2025-05-01) -
Laboratory Changes During Dupilumab Treatment for Atopic Dermatitis
by: D. Flor, et al.
Published: (2025-05-01) -
The interaction between the expression of CD23 molecule on B- lymphocytes and the level of specific IgE against molecular components of pollen in atopic dermatitis patients with and without dupilumab therapy
by: J. Čelakovská, et al.
Published: (2025-12-01) -
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01) -
Experience with dupilumab in patients with atopic dermatitis
by: E. A. Glukhova, et al.
Published: (2023-07-01)